報價延遲最少15分鐘:2026/10/01 14:02 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
104.065 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
2.07/5.68
|
|
企業價值
6.01B
|
| 資產負債 |
|
每股賬面淨值
18.40
|
| 現金流量 |
|
現金流量率
0.07
|
| 損益表 |
|
收益
1.33B
|
|
每股收益
27.24
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, thecompany operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells. |
